Roivant Sciences Ltd

ROIV

NASDAQ. Currency in USD

6.59 -0.73 ( -9.97% )

Real time prices: December 19

Market Cap.
4.78B
Beta (5Y monthly)
1.86
Price/Earnings
-
EPS (TTM)
-1.70
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
2.24M
1y Target Est.
11.50
Day's Range
6.43
-
7.38
52 Week's Range
2.52
-
7.53

Historical Summary

Performance
EPS growth
Share Buybacks

About Roivant Sciences Ltd

Sector
Healthcare
Industry
Biotechnology
Website
https://roivant.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
684.79M
Employees
863
Address
11-12 St. James?s Square, London, United Kingdom, SW1Y 4LB
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Latest news

Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday

Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst...
By Benzinga - 6 weeks ago

COP 0.00%
MRNA -1.76%
LHX -3.62%
XYL -1.30%
WPC 0.30%
ROIV -9.97%
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug

Roivant Sciences (ROIV), Pfizer's (PFE) new Vant company will take care of funding the global...
By Zacks Investment Research - 8 weeks ago

PFE -0.08%
GILD -0.39%
VRTX -4.33%
ROIV -9.97%
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal
Pharma Stock Roundup: PFE & AZN Ink New M&A Deals, LLY Meets Alzheimer's Study Goal

Pfizer (PFE) and Roivant Sciences (ROIV) form a new Roivant subsidiary to develop an inflammatory...
By Zacks Investment Research - 8 weeks ago

LLY -0.58%
PFE -0.08%
AZN -0.69%
BIIB -0.21%
ROIV -9.97%
Why Roivant Sciences' Shares Are Up Thursday
Why Roivant Sciences' Shares Are Up Thursday

The company is collaborating with Pfizer to create a portfolio company to develop an encouraging...
By The Motley Fool - 8 weeks ago

PFE -0.08%
ROIV -9.97%
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%
Pinterest To $23? Plus This Analyst Slashes PT On Neoleukin Therapeutics By More Than 90%

Rosenblatt raised the price target on Pinterest, Inc. (NYSE: PINS) from $21 to $23. Rosenblatt...
By Benzinga - 10 weeks ago

PINS -2.54%
ROIV -9.97%
LESL -0.41%
TDUP -15.08%
GMDA -4.10%
XGN -3.24%
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%

Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to...
By Benzinga - 10 weeks ago

ROIV -9.97%
NTLA -2.50%
JOBY -4.14%
CMBM 3.05%
GMDA -4.10%
NLTX 1.75%
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates

Roivant Sciences Ltd. (ROIV) delivered earnings and revenue surprises of -2.44% and 86.73%, respectively, for...
By Zacks Investment Research - 11 weeks ago

ROIV -9.97%
EVGN -2.94%
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates
Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates

Atyr Pharma (LIFE) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the...
By Zacks Investment Research - 11 weeks ago

ROIV -9.97%
LIFE -1.38%
Next page